How to read an FDA import alert

An import alert is not a recall and it is not a warning letter. It is a standing instruction to FDA’s own front-line staff at every U.S. port of entry: hold this firm’s shipments, or this specific product, without inspecting them first. Nothing about the product changes on the day it goes on the list — what changes is who has to prove it is admissible, and when.

What Detention Without Physical Examination actually does

Most imported shipments never see a human FDA reviewer. A product enters, clears customs, and moves on, screened at most by an automated risk model. Detention Without Physical Examination flips that default for one firm, one product line, or sometimes one country of origin: every matching shipment is detained on arrival, and the importer has to prove it is admissible before FDA will release it, typically by submitting private lab testing or other evidence tied to that specific shipment. FDA doesn’t have to test the product itself and doesn’t have to prove a violation before detaining it — the Section 801(a) standard only requires that the product “appears” to be adulterated or misbranded, based on the firm’s own history or a pattern FDA has already documented. That is a meaningfully lower bar than what supports a warning letter, which is why an import alert can look sudden from the outside even when it reflects months of an inspection or sampling history the firm already knew about.

Reading an entry on the list

Each import alert has a number (format like 89-08) and a plain-language title describing what it covers — a specific firm, a category of product from a specific country, or a violation pattern across an industry. Under that number sits a list of named firms and products, each carrying a “red list” or “green list” designation: red means detain on sight, green means a specific product or shipper has demonstrated compliance and is exempted from the alert that otherwise covers its category. It is common for a firm to be red-listed under one alert and still ship other products freely — the alert applies to the specific listing, not automatically to everything the firm makes. The entry also cites the statutory basis, adulteration or misbranding or both, which tells you whether the underlying concern is about the product itself (contamination, a labeling gap, missing registration) or about the firm’s manufacturing controls more broadly — the same distinction that shows up in a warning letter or an Untitled Letter.

Import alerts sit at a different point in FDA’s enforcement toolkit than a warning letter or an Untitled Letter — they act on shipments rather than on a firm’s marketing claims or manufacturing practices directly, and they can move faster because the legal standard behind them is lower. If you work with a contract manufacturer or a supplier outside the U.S., the import alert database is worth checking on its own, independent of whatever else you already know about that firm.